Skip to main content
Figure 2 | Genome Biology

Figure 2

From: Polygenic in vivovalidation of cancer mutations using transposons

Figure 2

Tumours generated in animals with transposons. (a) An F0 chimaera (animal id PLKD4.1a) that presented with hepatocellular carcinoma in two liver lobes (m1 and m2), histological sections from both tumours visualised with haemotoxylin and eosin (H&E) stains. (b) Transposon expression (RT-PCR using cDNA) and representation (PCR using genomic DNA (gDNA)) in two tumour samples and normal lung. (c) An F1 animal (id PLKH1.4b) that presented with a solid lymphoma tumour (top panel), H&E histological section. Serial subcutaneous transplants of the tumour in NSG mice gave rise to secondary (middle panel) and tertiary tumours (lower panel). (d) Transposon expression of PLKH1.4b in the serially transplanted tumour, cell lines derived from the primary and secondary transplanted tumours, and normal kidney tissues. (e) Colony forming assay of different DGKB alleles in cooperation with HRAS.V12 using Ink/Arf mutant MEFs. MYC is a positive control. Error bars denote standard deviation, P value from two-tailed T-test compared to HRAS.V12 alone. (f) Relative activity of different DGKB alleles as measured by phosphatidic acid (PA) production. (g) Number of mutated genes unique to and shared between two regions of a single lymphoma that was exome-sequenced. Known cancer genes with mutations are shown.

Back to article page